Thyroid Cancer

Oncology
15
Pipeline Programs
11
Companies
19
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
9
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
6100%
+ 14 programs with unclassified modality

On Market (1)

Approved therapies currently available

E
LENVIMAApproved
lenvatinib
Eisai
Kinase Inhibitor [EPC]oral2015

Competitive Landscape

11 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
7 programs
1
4
1
1
LenvatinibPhase 3Small Molecule1 trial
E7080 capsulePhase 21 trial
Irofulven + capecitabinePhase 21 trial
LenvatinibPhase 2Small Molecule1 trial
LenvatinibPhase 2Small Molecule1 trial
+2 more programs
Active Trials
NCT03533361Approved For Marketing
NCT00718770Completed10Est. Feb 2013
NCT01728623Completed51Est. Oct 2015
+4 more trials
CT
2 programs
1
1
AL2846 CapsulesPhase 31 trial
Anlotinib hydrochloridePhase 21 trial
Active Trials
NCT04952493UnknownEst. Jul 2024
NCT06860971RecruitingEst. Jan 2028
Sanofi
SanofiPARIS, France
3 programs
1
1
Euthyroid GroupPhase 21 trial
Interdisciplinary Team-Based ApproachPhase 1/21 trial
AZD6244N/A
Active Trials
NCT01994200Withdrawn0Est. Jun 2016
NCT00181168Completed63Est. Sep 2003
Pfizer
PfizerNEW YORK, NY
1 program
1
AG 6013736Phase 21 trial
Active Trials
NCT00176748Completed3Est. Jun 2009
Kura Oncology
Kura OncologySAN DIEGO, CA
1 program
1
TipifarnibPhase 2Small Molecule1 trial
Active Trials
NCT02383927Completed63Est. Dec 2020
Genentech
GenentechCA - Oceanside
1 program
1
VemurafenibPhase 2Small Molecule1 trial
Active Trials
NCT01709292Active Not Recruiting24Est. Sep 2026
Celldex Therapeutics
1 program
1
KTN3379Phase 11 trial
Active Trials
NCT02456701Completed7Est. Oct 2016
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
AZD6244N/A1 trial
Active Trials
NCT00970359Completed24Est. Apr 2013
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
Molecular Markers in Thyroid CancerN/A1 trial
Active Trials
NCT00598364Completed847Est. Oct 2010
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Redifferentiation with retinoid acidN/A1 trial
Active Trials
NCT03363347Completed25Est. Dec 2014
Genomics
GenomicsUK - Oxford
1 program
ctDNA in Patients With Thyroid NodulesN/A1 trial
Active Trials
NCT02778412Terminated66Est. Aug 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Chia Tai TianQing Pharmaceutical GroupAL2846 Capsules
EisaiLenvatinib
Chia Tai TianQing Pharmaceutical GroupAnlotinib hydrochloride
EisaiLenvatinib
Kura OncologyTipifarnib
GenentechVemurafenib
EisaiE7080 capsule
EisaiLenvatinib
PfizerAG 6013736
EisaiIrofulven + capecitabine
SanofiEuthyroid Group
SanofiInterdisciplinary Team-Based Approach
Celldex TherapeuticsKTN3379
EisaiBexarotene
GenomicsctDNA in Patients With Thyroid Nodules

Showing 15 of 18 trials with date data

Clinical Trials (19)

Total enrollment: 1,968 patients across 19 trials

NCT06860971Chia Tai TianQing Pharmaceutical GroupAL2846 Capsules

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

Start: Apr 2025Est. completion: Jan 2028
Phase 3Recruiting
NCT01321554EisaiLenvatinib

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

Start: Mar 2011Est. completion: Mar 2019392 patients
Phase 3Completed
NCT04952493Chia Tai TianQing Pharmaceutical GroupAnlotinib hydrochloride

Anlotinib or Penpulimab in Combination With RAI for DTC

Start: Sep 2021Est. completion: Jul 2024
Phase 2Unknown
NCT02702388EisaiLenvatinib

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Start: Jun 2017Est. completion: Sep 2020241 patients
Phase 2Completed
NCT02383927Kura OncologyTipifarnib

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Start: May 2015Est. completion: Dec 202063 patients
Phase 2Completed
NCT01709292GenentechVemurafenib

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Start: Nov 2012Est. completion: Sep 202624 patients
Phase 2Active Not Recruiting
NCT01728623EisaiE7080 capsule

A Study of E7080 in Subjects With Advanced Thyroid Cancer

Start: Sep 2012Est. completion: Oct 201551 patients
Phase 2Completed
NCT00784303EisaiLenvatinib

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Start: Nov 2008Est. completion: Mar 2019117 patients
Phase 2Completed
NCT00176748PfizerAG 6013736

Treatment for Patients With Metastatic Thyroid Cancer

Start: Jul 2005Est. completion: Jun 20093 patients
Phase 2Completed
NCT00124527EisaiIrofulven + capecitabine

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

Start: Mar 2005Est. completion: Aug 200635 patients
Phase 2Completed
NCT00181168SanofiEuthyroid Group

Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer

Start: Mar 2001Est. completion: Sep 200363 patients
Phase 2Completed
NCT01994200SanofiInterdisciplinary Team-Based Approach

Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients

Start: Sep 2014Est. completion: Jun 20160
Phase 1/2Withdrawn
NCT02456701Celldex TherapeuticsKTN3379

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Start: Jun 2015Est. completion: Oct 20167 patients
Phase 1Completed
NCT00718770EisaiBexarotene

A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

Start: Nov 2008Est. completion: Feb 201310 patients
Phase 1Completed
NCT03533361EisaiLenvatinib

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

N/AApproved For Marketing
NCT02778412GenomicsctDNA in Patients With Thyroid Nodules

ctDNA in Patients With Thyroid Nodules

Start: May 2016Est. completion: Aug 201766 patients
N/ATerminated
NCT00970359AstraZenecaAZD6244

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Start: Sep 2009Est. completion: Apr 201324 patients
N/ACompleted
NCT03363347Heidelberg PharmaRedifferentiation with retinoid acid

BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

Start: Jan 2008Est. completion: Dec 201425 patients
N/ACompleted
NCT00598364Knight TherapeuticsMolecular Markers in Thyroid Cancer

Molecular Markers in Thyroid Cancer

Start: Feb 2007Est. completion: Oct 2010847 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
Just now
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
Just now

Office Administrator

SystImmune
1m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
11m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
15m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
15m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,968 patients
11 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)